 "Lupin ties up with Amman Pharma for commercialisation of biosimilar product")
Drug firm Lupin on Friday said it has tied up with Amman Pharma to market a biosimilar product in the Middle East region.
The company has inked a licensing pact for the commercialisation and marketing of Ranibizumab, a biosimilar of Lucentis, in various countries including Saudi Arabia, UAE, Iraq and Lebanon.
Ranibizumab is indicated for the treatment of patients with neovascular age-related macular degeneration, macular edema following retinal vein occlusion (RVO) and diabetic macular edema, among others.
Shares of the company on Friday ended 2.04 per cent down at Rs 1,180.20 apiece on the BSE.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)